CN112654619A - 三环并呋喃取代哌啶二酮类化合物 - Google Patents
三环并呋喃取代哌啶二酮类化合物 Download PDFInfo
- Publication number
- CN112654619A CN112654619A CN201980058617.XA CN201980058617A CN112654619A CN 112654619 A CN112654619 A CN 112654619A CN 201980058617 A CN201980058617 A CN 201980058617A CN 112654619 A CN112654619 A CN 112654619A
- Authority
- CN
- China
- Prior art keywords
- reaction mixture
- reaction
- ethyl acetate
- compound
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一系列带有三环并呋喃取代哌啶二酮类化合物,及其在制备治疗与CRBN蛋白相关疾病药物中的应用,具体公开了式(I)所示衍生化合物或其药学上可接受的盐。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811048512X | 2018-09-07 | ||
CN201811048512 | 2018-09-07 | ||
CN2018113564157 | 2018-11-14 | ||
CN201811356415 | 2018-11-14 | ||
CN201910225326 | 2019-03-22 | ||
CN2019102253267 | 2019-03-22 | ||
PCT/CN2019/104992 WO2020048547A1 (zh) | 2018-09-07 | 2019-09-09 | 三环并呋喃取代哌啶二酮类化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112654619A true CN112654619A (zh) | 2021-04-13 |
CN112654619B CN112654619B (zh) | 2022-08-30 |
Family
ID=69722192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980058617.XA Active CN112654619B (zh) | 2018-09-07 | 2019-09-09 | 三环并呋喃取代哌啶二酮类化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11319330B2 (zh) |
EP (1) | EP3848371A4 (zh) |
JP (1) | JP7323603B2 (zh) |
KR (1) | KR102605291B1 (zh) |
CN (1) | CN112654619B (zh) |
WO (1) | WO2020048547A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210056397A (ko) * | 2018-09-07 | 2021-05-18 | 메드샤인 디스커버리 아이엔씨. | 삼환식 치환 피페리딘 디온계 화합물 |
BR112021004269A2 (pt) * | 2018-09-07 | 2021-05-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, relacionada à proteína crbn e método para tratamento da mesma |
WO2021047674A1 (zh) * | 2019-09-12 | 2021-03-18 | 南京明德新药研发有限公司 | 作为crbn蛋白调节剂的双并环类化合物 |
CN115380026B (zh) * | 2020-03-17 | 2023-11-07 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
TWI807697B (zh) * | 2021-03-17 | 2023-07-01 | 大陸商南京明德新藥研發有限公司 | 呋喃稠環取代的戊二醯亞胺類化合物 |
WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
TW202325300A (zh) * | 2021-11-18 | 2023-07-01 | 大陸商正大天晴藥業集團股份有限公司 | 稠合醯亞胺類衍生物及其應用 |
WO2024037616A1 (zh) * | 2022-08-19 | 2024-02-22 | 正大天晴药业集团股份有限公司 | 包含环己基的化合物 |
WO2024055994A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京明德新药研发有限公司 | 萘并呋喃取代的戊二酰亚胺类化合物的晶型、制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379774A (zh) * | 1999-08-18 | 2002-11-13 | 阿斯特拉曾尼卡有限公司 | 化合物 |
WO2004063190A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivates as ppar modulators |
EP1690538A1 (en) * | 2003-12-02 | 2006-08-16 | Shionogi & Co., Ltd. | Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
CN101877966A (zh) * | 2007-07-02 | 2010-11-03 | 葛兰素史密丝克莱恩有限责任公司 | 类法尼醇x受体激动剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2829592A1 (en) * | 2011-03-11 | 2012-09-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
CN108245518B (zh) | 2012-08-09 | 2021-08-31 | 细胞基因公司 | 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法 |
KR20150054962A (ko) | 2012-09-10 | 2015-05-20 | 셀진 코포레이션 | 국소 진행성 유방암의 치료방법 |
EP3455218A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197051A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
CA3050309A1 (en) * | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
US11292792B2 (en) * | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
KR20210056397A (ko) * | 2018-09-07 | 2021-05-18 | 메드샤인 디스커버리 아이엔씨. | 삼환식 치환 피페리딘 디온계 화합물 |
BR112021004269A2 (pt) * | 2018-09-07 | 2021-05-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, relacionada à proteína crbn e método para tratamento da mesma |
SG11202109024YA (en) * | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
-
2019
- 2019-09-09 KR KR1020217010237A patent/KR102605291B1/ko active IP Right Grant
- 2019-09-09 WO PCT/CN2019/104992 patent/WO2020048547A1/zh unknown
- 2019-09-09 JP JP2021512772A patent/JP7323603B2/ja active Active
- 2019-09-09 EP EP19857640.7A patent/EP3848371A4/en active Pending
- 2019-09-09 CN CN201980058617.XA patent/CN112654619B/zh active Active
- 2019-09-09 US US17/274,236 patent/US11319330B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1379774A (zh) * | 1999-08-18 | 2002-11-13 | 阿斯特拉曾尼卡有限公司 | 化合物 |
WO2004063190A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivates as ppar modulators |
EP1690538A1 (en) * | 2003-12-02 | 2006-08-16 | Shionogi & Co., Ltd. | Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
CN101877966A (zh) * | 2007-07-02 | 2010-11-03 | 葛兰素史密丝克莱恩有限责任公司 | 类法尼醇x受体激动剂 |
Also Published As
Publication number | Publication date |
---|---|
JP7323603B2 (ja) | 2023-08-08 |
EP3848371A4 (en) | 2022-06-08 |
JP2022502355A (ja) | 2022-01-11 |
CN112654619B (zh) | 2022-08-30 |
KR102605291B1 (ko) | 2023-11-23 |
WO2020048547A1 (zh) | 2020-03-12 |
KR20210057091A (ko) | 2021-05-20 |
US11319330B2 (en) | 2022-05-03 |
EP3848371A1 (en) | 2021-07-14 |
US20210317138A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112654619B (zh) | 三环并呋喃取代哌啶二酮类化合物 | |
CN112689627B (zh) | 三环取代哌啶二酮类化合物 | |
CN112533916B (zh) | 一种作用于crbn蛋白的三并环类化合物 | |
CN115298174A (zh) | 嘧啶并杂环类化合物及其应用 | |
WO2021259331A1 (zh) | 八元含n杂环类化合物 | |
CN115380026A (zh) | 蛋白降解调节剂与其使用方法 | |
CN112771045B (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
KR20220059517A (ko) | 소분자 pd-1/pd-l1 억제제로서의 화합물 및 이의 용도 | |
CN114174282A (zh) | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 | |
CN116761799A (zh) | 嘧啶并吡喃类化合物 | |
CN114761411A (zh) | 作为erk抑制剂的螺环类化合物及其应用 | |
CN114401962A (zh) | 作为crbn蛋白调节剂的双并环类化合物 | |
CN113825755A (zh) | 作为irak4抑制剂的咪唑并吡啶类化合物 | |
KR20230154953A (ko) | 푸란 축합 고리로 치환된 글루타르이미드계 화합물 | |
CN113825757A (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
CN111315750B (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
WO2023208127A1 (zh) | 杂芳基取代的双环化合物及其应用 | |
CN112955453B (zh) | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 | |
CN112574278A (zh) | 作为蛋白降解剂杂环类化合物及其制备方法和医药应用 | |
WO2023045978A1 (zh) | 2,6-哌啶二酮类化合物与其应用 | |
TW201930268A (zh) | 吲哚胺2,3-雙加氧酶抑制劑以及它們在醫學上的應用 | |
WO2023001069A1 (zh) | 大环酰胺类化合物及其应用 | |
CN115515963A (zh) | 嘧啶三并环类化合物及其应用 | |
CN114072401A (zh) | 作为irak4和btk多靶点抑制剂的噁唑类化合物 | |
CN111971285A (zh) | 咪唑并吡咯酮化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40040309 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |